ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Isturisa® continues to show promise in Cushing’s disease
March 25, 2021New Phase III trial results show 81 percent of Cushing’s disease patients who received Isturisa® (osilodrostat) had sustained normalisation of mean urinary free cortisol levels. -
FDA approves Isturisa (osilodrostat) treatment for Cushing’s disease
March 10, 2020The FDA has approved Isturisa for Cushing’s disease treatment after it demonstrated significant efficacy in clinical trials. -
FDA approves new treatment for adults with Cushing's disease
March 09, 2020The U.S. Food and Drug Administration approved Isturisa (osilodrostat) oral tablets for adults with Cushing’s disease who either cannot undergo pituitary gland surgery or have undergone the surgery but still have the disease.
Pharma Sources Insight January 2025
